On November 22, 2024, Ozan Pamir, Chief Financial Officer of ChromaDex Corp, purchased 2,907 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns a total of 2,907.197 shares.
ChromaDex Corp (CDXC, Financial) is a company that specializes in the development and commercialization of evidence-based dietary supplements and skin care products. The company's flagship ingredient, nicotinamide riboside, is marketed as a healthy aging supplement.
The insider transaction history for ChromaDex Corp indicates that there have been two insider buys and one insider sell over the past year. Ozan Pamir has purchased a total of 2,907 shares in the past year and has not sold any shares.
On the day of the recent purchase, shares of ChromaDex Corp were trading at $7.36, giving the stock a market cap of $568.292 million. The company's price-earnings ratio stands at 744.00, which is significantly higher than the industry median of 17.695 and the company's historical median price-earnings ratio.
The GF Value of ChromaDex Corp is estimated at $2.14, resulting in a price-to-GF-Value ratio of 3.44. This suggests that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company's past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
